HomeCompareGULRF vs ABBV

GULRF vs ABBV: Dividend Comparison 2026

GULRF yields 5.54% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $81.7K in total portfolio value
10 years
GULRF
GULRF
● Live price
5.54%
Share price
$8.34
Annual div
$0.46
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$0.57
Full GULRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GULRF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGULRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GULRF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GULRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GULRF
Annual income on $10K today (after 15% tax)
$471.17/yr
After 10yr DRIP, annual income (after tax)
$0.48/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,055.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GULRF + ABBV for your $10,000?

GULRF: 50%ABBV: 50%
100% ABBV50/50100% GULRF
Portfolio after 10yr
$61.5K
Annual income
$12,386.16/yr
Blended yield
20.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GULRF
No analyst data
Altman Z
1.8
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GULRF buys
0
ABBV buys
0
No recent congressional trades found for GULRF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGULRFABBV
Forward yield5.54%3.06%
Annual dividend / share$0.46$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$20.6K$102.3K
Annual income after 10y$0.57$24,771.77
Total dividends collected$563.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GULRF vs ABBV ($10,000, DRIP)

YearGULRF PortfolioGULRF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,977$277.16$11,550$430.00$573.00ABBV
2$11,888$142.17$13,472$627.96$1.6KABBV
3$12,792$71.94$15,906$926.08$3.1KABBV
4$13,723$36.18$19,071$1,382.55$5.3KABBV
5$14,702$18.14$23,302$2,095.81$8.6KABBV
6$15,740$9.08$29,150$3,237.93$13.4KABBV
7$16,847$4.54$37,536$5,121.41$20.7KABBV
8$18,028$2.27$50,079$8,338.38$32.1KABBV
9$19,291$1.14$69,753$14,065.80$50.5KABBV
10$20,642$0.57$102,337$24,771.77$81.7KABBV

GULRF vs ABBV: Complete Analysis 2026

GULRFStock

Guoco Group Limited, an investment holding company, engages in the principal investment, property investment and development, hospitality and leisure, and financial service businesses. The company's Principal Investment segment offers debt, equity, and direct investments, as well as treasury operations with trading and strategic investments in global capital markets. Its Property Development and Investment segment develops residential and commercial properties, as well as holds properties for rental income in Singapore, China, Malaysia, Vietnam, and Hong Kong. The company's Hospitality and Leisure Business segment owns, leases, and manages hotels; and operates gaming and leisure businesses in the United Kingdom, Spain, and Belgium. This segment owns and operates hotels under Guoman, Thistle, and Thistle Express brands, as well as operates Hard Rock Hotel London under a third party brand. It offers Mecca, a bingo operator in Great Britain with 125 venues and a digital channel, www.meccabingo.com that provides a selection of games from bingo to slot machines; Grosvenor Casinos, a casino operator with 70 casinos in Great Britain and casino in Belgium, as well as its digital channel, www.grosvenorcasinos.com; and Enracha, which offers a range of popular games and sports betting through its 10 venues in Spain and its digital channels www.enracha.es, www.yobingo.es, and www.yocasino.es. Its Financial Services segment provides commercial and consumer, Islamic, and investment banking services; and life and general insurance, Takaful insurance, fund management and unit trust, corporate advisory, and stock broking services. The company also offers royalty entitlement of Bass Strait's oil and gas production, as well as manufactures, markets, and distributes health products. The company is based in Central, Hong Kong. Guoco Group Limited is a subsidiary of GuoLine Overseas Limited.

Full GULRF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GULRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GULRF vs SCHDGULRF vs JEPIGULRF vs OGULRF vs KOGULRF vs MAINGULRF vs JNJGULRF vs MRKGULRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.